Hospitals | May 11, 2022
Dr. Agarwal's Health Care raises over Rs 1,000 crore from TPG Growth and Temasek
The company also raised Rs 270 crore investment from Temasek in 2019
The company also raised Rs 270 crore investment from Temasek in 2019
Cipla has reported consolidated financial results for the period ended March 31, 2022
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
The company intends to begin using drones to make deliveries of critical and emergency medical supplies, vaccines, and lifesaving drugs after getting the prerequisite regulatory approvals
This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr. Reddy's will handle local clinical development, registration, marketing and sales
The partners also aim to expand their work to Latin America for the first time
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
Subscribe To Our Newsletter & Stay Updated
